Thioguanine: A potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine

Marla C. Dubinsky, Edward J. Feldman, Maria T. Abreu, Stephan R. Targan, Eric A. Vasiliauskas

Research output: Contribution to journalArticle

90 Scopus citations

Abstract

OBJECTIVE: Approximately 10% of inflammatory bowel disease (IBD) patients receiving 6-mercaptopurine (6-MP) or azathioprine (AZA) develop drug hypersensitivity reactions necessitating early discontinuation of these traditional thiopurines. These allergic reactions typically reoccur upon rechallenge. Our recently published pilot study suggested that thioguanine (6-TG), a closely related thiopurine, was efficacious and well tolerated in IBD patients resistant to 6-MP/AZA. The aim of this study was to determine if hypersensitivity reactions to 6-MP/AZA reoccur with 6-TG therapy. METHODS: IBD patients allergic to 6-MP and/or AZA were treated with 6-TG as an alternate thiopurine. Hypersensitivity reactions to 6-MP/AZA must have been documented within 6 wk of 6-MP/AZA initiation. RESULTS: 6-TG was initiated in 21 IBD patients at a median (range) dose of 20 (10-40) mg/day. 6-TG hypersensitivity reaction occurred in only four of 21 (19%) patients after a median time interval of 9 days. Pancreatitis did not reoccur with 6-TG. Eighty-two percent of 6-TG tolerant patients were assessed as improved at last follow-up. CONCLUSIONS: These results suggest that 6-TG may be considered as a possible alternate thiopurine in patients allergic to traditional 6-MP/AZA. Despite these favorable results, candidates for 6-TG should be selected with caution, and its use should be reserved for IBD patients well informed about potential toxicities.

Original languageEnglish (US)
Pages (from-to)1058-1063
Number of pages6
JournalAmerican Journal of Gastroenterology
Volume98
Issue number5
DOIs
StatePublished - May 1 2003

    Fingerprint

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this